Shares of PetMed Express, Inc. (NASDAQ:PETS) have received a consensus rating of “Hold” from the eight brokerages that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and three have issued a buy recommendation on the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $40.00.

A number of research firms recently commented on PETS. ValuEngine lowered PetMed Express from a “buy” rating to a “hold” rating in a research report on Monday, October 2nd. Credit Suisse Group restated an “underperform” rating and issued a $19.00 price objective on shares of PetMed Express in a research note on Monday, October 2nd. Zacks Investment Research downgraded PetMed Express from a “strong-buy” rating to a “hold” rating in a research note on Monday, September 25th. Sidoti upgraded PetMed Express from a “neutral” rating to a “buy” rating and set a $47.00 price objective for the company in a research note on Thursday, August 24th. Finally, BidaskClub downgraded PetMed Express from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, August 22nd.

COPYRIGHT VIOLATION WARNING: This piece was reported by American Banking News and is the property of of American Banking News. If you are reading this piece on another domain, it was illegally copied and republished in violation of US and international copyright and trademark legislation. The correct version of this piece can be read at https://www.americanbankingnews.com/2017/10/13/petmed-express-inc-pets-given-average-recommendation-of-hold-by-brokerages.html.

In other PetMed Express news, Director Robert C. Schweitzer sold 2,500 shares of the company’s stock in a transaction on Tuesday, August 1st. The stock was sold at an average price of $49.18, for a total value of $122,950.00. Following the completion of the transaction, the director now owns 88,834 shares in the company, valued at approximately $4,368,856.12. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Bruce S. Rosenbloom sold 6,833 shares of the company’s stock in a transaction on Thursday, July 27th. The shares were sold at an average price of $50.18, for a total value of $342,879.94. Following the completion of the transaction, the chief financial officer now owns 18,534 shares of the company’s stock, valued at approximately $930,036.12. The disclosure for this sale can be found here. Insiders sold a total of 19,333 shares of company stock valued at $949,730 in the last 90 days. Corporate insiders own 4.00% of the company’s stock.

A number of large investors have recently made changes to their positions in the business. Pinebridge Investments L.P. grew its stake in PetMed Express by 1.0% in the 2nd quarter. Pinebridge Investments L.P. now owns 2,704 shares of the company’s stock valued at $110,000 after purchasing an additional 27 shares during the period. Arizona State Retirement System grew its stake in PetMed Express by 0.9% in the 1st quarter. Arizona State Retirement System now owns 10,667 shares of the company’s stock valued at $215,000 after purchasing an additional 100 shares during the period. Texas Permanent School Fund grew its stake in PetMed Express by 0.8% in the 2nd quarter. Texas Permanent School Fund now owns 14,986 shares of the company’s stock valued at $608,000 after purchasing an additional 125 shares during the period. Advisor Group Inc. grew its stake in PetMed Express by 0.7% in the 2nd quarter. Advisor Group Inc. now owns 24,844 shares of the company’s stock valued at $1,009,000 after purchasing an additional 179 shares during the period. Finally, QS Investors LLC grew its stake in PetMed Express by 4.0% in the 2nd quarter. QS Investors LLC now owns 9,324 shares of the company’s stock valued at $379,000 after purchasing an additional 356 shares during the period. Hedge funds and other institutional investors own 78.91% of the company’s stock.

PetMed Express (NASDAQ:PETS) last released its quarterly earnings results on Monday, July 24th. The company reported $0.45 EPS for the quarter, beating analysts’ consensus estimates of $0.38 by $0.07. The business had revenue of $79.66 million during the quarter, compared to analyst estimates of $77.32 million. PetMed Express had a return on equity of 28.67% and a net margin of 10.34%. PetMed Express’s quarterly revenue was up 9.9% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.32 EPS.

PetMed Express Company Profile

PetMed Express, Inc (PetMed Express), doing business as 1800PetMeds, is a pet pharmacy. The Company markets prescription and non-prescription pet medications, and other health products for dogs and cats, direct to the consumer. It offers a selection of products for dogs and cats. Its product line contains approximately 3,000 stock keeping units (SKUS) of pet medications, health products and supplies.

Analyst Recommendations for PetMed Express (NASDAQ:PETS)

Receive News & Ratings for PetMed Express Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PetMed Express Inc. and related companies with MarketBeat.com's FREE daily email newsletter.